Loading...
Loading...
VINC| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 11.7M |
| Operating I/L | -11.7M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.3M |
| Pretax | -11.2M |
| Income Tax Expense | -0.5M |
| Net Income/Loss | -11.2M |
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in cancer treatment. The company's lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor designed for patients with advanced cancer. Additionally, Vincerx Pharma has a range of preclinical stage product candidates, including VIP217, VIP236, VIP943, and VIP924, targeting various forms of cancer. These products form the core of the company's revenue stream, as they aim to bring effective and advanced treatment options to patients battling cancer.
